Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.205 SEK | +0.72% | +4.99% | -33.57% |
Mar. 04 | Intervacc AB Announces Changes in the Nomination Committee | CI |
Feb. 28 | Intervacc's Acting CEO Assumes Role Permanently | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-33.57% | 28.99M | D | ||
-3.46% | 102B | B+ | ||
+1.41% | 96.09B | B+ | ||
+2.13% | 22.28B | B | ||
-15.84% | 21.4B | B+ | ||
-9.51% | 18.14B | A- | ||
-39.98% | 17.02B | A- | ||
-14.65% | 16.09B | B | ||
+4.39% | 13.83B | C+ | ||
+31.35% | 11.97B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IVACC Stock
- Ratings Intervacc AB